What does Kymera do?
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. State of Possible: Kymera Therapeutics Founder and CEO Nello Mainolfi talks protein degradation, his take on recent industry data, and updates on the company’s programs, including a new one to come.
Who owns Kymera?
Palladium Equity Partners Acquires Kymera International from Platinum Equity. Who are Kymera International’s investors? Edmond de Rothschild Private Equity and Palladium Equity Partners have invested in Kymera International.
How big is Kymera Therapeutics?
The current market capitalization of Kymera Therapeutics is $1. B. Total Valuation KYMR has a market cap or net worth of $2. The enterprise value is $1.